ИГИван Георгиевич Гафтон

Иван Георгиевич Гафтон

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Иван Георгиевич Гафтон has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    History of joint replacement

    by Evgeny M. Senchurov, S. A. Kulyova, G. I. Gafton, Yu. V. Gudz, I. G. Gafton, G. V. Zinoviev, E. A. Mikhailova

    The article presents the history of the development of prosthetic joints. After pioneering work using ivory and metal for prosthetics, reconstruction became a significant achievement and attempts to replace all major joints were documented. An expanded understanding of the processes and basic principles implemented in modern prostheses can become the basis for further improving their functional characteristics and service life, as well as for increasing the level of care provided and the degree of patient satisfaction.

  • Open Access

    Efficacy and Safety of Postoperative Stereotactic Radiotherapy to the Prostate Bed (Long-Term Follow-Up Results)

    by Никита Олегович Кузнецов, Роман Владимирович Новиков, Сергей Николаевич Новиков, Екатерина Евгеньевна Самарцева, Николай Дмитриевич Ильин, Иван Георгиевич Гафтон, Юрий Олегович Мережко, Филипп Евгеньевич Антипов, Мария Юрьевна Готовчикова, Юлия Сергеевна Мельник, et al.

    Introduction. Despite advances in the surgical management of prostate cancer (PCa), postoperative recurrence remains a significant clinical challenge. Contemporary approaches to postoperative radiation therapy, including stereotactic body radiation therapy (SBRT), offer promising opportunities to enhance therapeutic efficacy and reduce treatment duration while maintaining an acceptable toxicity profile. Aim. To evaluate the long-term efficacy and safety of postoperative SBRT directed to the prostate bed (PB) in patients with recurrent PCa following radical prostatectomy (RP). Materials and Methods. A prospective single-center study enrolled 56 patients with biochemical recurrence of PCa after RP. All patients received SBRT to the PB with a total dose of 35 Gy delivered in five fractions. The median follow-up duration was 38 months. Oncological outcomes, radiation-induced toxicity (assessed using RTOG criteria), and quality of life parameters were evaluated. Results. Biochemical recurrence occurred in 13 patients (23.2 %), including three cases (5.4 %) of local relapse within the PB. Disease-free survival was maintained in 76.8 % of patients at the final follow-up, with local control achieved in 94.6 % of cases. Acute grade I genitourinary toxicity was observed in 11 patients (19.6 %). Late toxicities included grade I–II genitourinary effects in 25 patients (44.6 %) and grade I–II gastrointestinal effects in five patients (8.9 %). No grade III or higher radiation-related complications were reported. Quality of life measures remained stable compared to baseline values. Conclusion. Postoperative SBRT targeting the PB provides excellent local control and is well tolerated. This treatment approach represents an effective and safe therapeutic option for patients with recurrent PCa following surgical intervention.

  • Open Access

    Vascular Reconstruction in Patients with Soft Tissue Sarcomas: Experience of N.N. Petrov National Medical Research Center of Oncology

    by Григорий Владимирович Зиновьев, Мария Альбертовна Гафтон, Андрей Владимирович Бородулин, Георгий Иванович Гафтон, Иван Георгиевич Гафтон, Михаил Сергеевич Синячкин, Екатерина Григорьевна Гнеева, Анжелика Александровна Салимова

    Введение. Саркомы мягких тканей — редкая и гетерогенная группа опухолей. Инвазия в кровеносные сосуды описана в 5 % случаев сарком мягких тканей, что ранее было показанием к проведению калечащих операций. Благодаря внедрению различных методов пластической и реконструктивной хирургии, показания к конечность-сохраняющим операциям возрастают. Материалы и методы. 12 пациентов в период с 1 июня 2020 г. по 1 декабря 2024 г. получили лечение в НМИЦ онкологии им. Н.Н. Петрова с саркомами мягких тканей в объеме: удаление опухоли мягких тканей конечности с резекцией магистральных сосудов с реконструкцией артерии. Результаты. Операции выполнены на верхней конечности в 4 (33,3 %) случаях, на нижней конечности — в 8. В 6 случаях выполнена резекция только артерии, в 6 случаях — резекция артерии и вены, при этом восстановление целостности венозного русла не производилось. В 11 случаях для реконструкции сосудистого русла использовалась аутовена пораженной конечности, в 1 случае использована большая подкожна вена с контралатеральной конечности. Случаев тромбоза протезированной артерии, как в раннем послеоперационном периоде, так и при дальнейшем наблюдении за пациентами, не зафиксировано. Средний показатель по этой шкале составил 80 %, что соответствует хорошим результатам. Выводы. Вовлечение сосудистых структур не является абсолютным показанием для проведения калечащей операции при саркомах мягких тканей, но для оптимизации результатов лечения необходимо соответствующее планирование и определение тактики в условиях референсного центра.

  • Open Access

    Pelvic endoprosthesis in tumor lesions: experience of N.N. Petrov National Medical Research Center of Oncology

    by G. I. Gafton, Y. V. Gudz, Г. В. Зиновьев, M. A. Ebert, I. G. Gafton, M. S. Sinyachkin, A. V. Borodulin, A. B. Gogolev

    Introduction. Oncological endoprosthesis for tumors of the pelvic bones is rare. It is associated with certain difficulties and is insufficiently investigated.The study objective is to evaluate the results of surgical treatment of patients with tumors of the pelvis performed between 2012 and 2021 at the N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included 23 patients with primary and secondary tumors of the pelvic bones who underwent limb-saving surgeries with substitution of the postresection defect with an endoprosthesis between 2012 and 2021. Mean follow-up duration was 19 months.Results. The most common postoperative complication was infection of the postoperative wound (n = 8; 35 %). Mechanical complications associated with the installed metallic prosthesis were observed in 4 (17 %) patients. Function al results were evaluated after 6 months using the Musculoskeletal Tumor Society Score (MSTS). Mean score per this scale was 53 % which corresponds to satisfactory outcome.Conclusion. Patients with malignant tumors of the pelvic bones should undergo treatment only in specialized medical facilities. Patients for organ-saving therapy should be carefully selected.